Pfizer Limited

Ramsgate Road, Sandwich, Kent, CT13 9NJ
Telephone: +44 (0)1304 616 161
Fax: +44 (0)1304 656 221

Summary of Product Characteristics last updated on the eMC: 30/09/2011
SPC Accupro Tablets 5mg, 10mg, 20mg & 40mg

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 30/09/2011 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 5.2 - Pharmacokinetic Properties
Date of revision of text on the SPC:   01-Aug-2011
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



Section 4.2 – Updated to include recommended wording for children

Section 5.1 and 5.2 – Updated to provide information on paediatric studies

Updated on 07/07/2009 and displayed until 30/09/2011
Reasons for adding or updating:
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 5.2 - Pharmacokinetic Properties
Date of revision of text on the SPC:   01-Jun-2009
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

 Section 4.3
  • Amendment of contraindication in pregnancy to state that Accupro is contraindicated during the second and third trimesters of pregnancy
  • Removal of contraindication in nursing mothers

Section 4.4

  • Addition of precautions for use in pregnancy

Section 4.6

  • Addition of precautions for use in pregnancy and lactation

Section 5.2

  • Addition of pharmacokinetic data on the presence of quinapril in breast milk

 

Updated on 30/03/2007 and displayed until 07/07/2009
Reasons for adding or updating:
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.2 - Posology and method of administration
Date of revision of text on the SPC:   03/2007
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

 

3 – Updated to include the full product description

4.2 – updated change use of BANs (british approved names) to INNs (international non-proprietary names)

Updated on 21/02/2007 and displayed until 30/03/2007
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
Date of revision of text on the SPC:   01/2007
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

4.2 – administrative changes to update cross referencing

4.3 – administrative changes to update cross referencing

4.5 – additional descriptive text regarding existing interactions

Updated on 21/02/2007 and displayed until 21/02/2007
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
Date of revision of text on the SPC:   01/2007
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

4.2 – administrative changes to update cross referencing

4.3 – administrative changes to update cross referencing

4.5 – additional descriptive text regarding existing interactions

Updated on 10/07/2006 and displayed until 21/02/2007
Reasons for adding or updating:
  • Change to section 3 - pharmaceutical form
Date of revision of text on the SPC:   06/2006
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 3 of SmPC was updated to reflect change in appearance of the finished tablets.

Updated on 07/07/2006 and displayed until 10/07/2006
Reasons for adding or updating:
  • Change to section 3 - pharmaceutical form
Date of revision of text on the SPC:   12/2005
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

CHANGE TO SECTION 3: from 'brown, elliptical film coated tablet imprinted with the dosage strength' to 'reddish-brown oval, biconvex film-coated tablet with debossing '40' on one side and 'PD 535'  on the other side'
Updated on 06/04/2006 and displayed until 07/07/2006
Reasons for adding or updating:
  • Change to section 4.2 - Posology and Method of Administration
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 10 (date of (partial) revision of the text
Updated on 06/01/2006 and displayed until 06/04/2006
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 28/09/2005 and displayed until 06/01/2006
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 28/09/2005 and displayed until 28/09/2005
Reasons for adding or updating:
  • New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC

Active Ingredients/Generics

 
   quinapril hydrochloride